Transcutaneous electrical nerve stimulation for knee osteoarthritis (Review)


This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2007, Issue 4

http://www.thecochranelibrary.com
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>PLAIN LANGUAGE SUMMARY</td>
<td>2</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>2</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>2</td>
</tr>
<tr>
<td>CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW</td>
<td>3</td>
</tr>
<tr>
<td>SEARCH METHODS FOR IDENTIFICATION OF STUDIES</td>
<td>3</td>
</tr>
<tr>
<td>METHODS OF THE REVIEW</td>
<td>4</td>
</tr>
<tr>
<td>DESCRIPTION OF STUDIES</td>
<td>4</td>
</tr>
<tr>
<td>METHODOLOGICAL QUALITY</td>
<td>4</td>
</tr>
<tr>
<td>RESULTS</td>
<td>5</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>5</td>
</tr>
<tr>
<td>AUTHORS’ CONCLUSIONS</td>
<td>7</td>
</tr>
<tr>
<td>POTENTIAL CONFLICT OF INTEREST</td>
<td>7</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>7</td>
</tr>
<tr>
<td>SOURCES OF SUPPORT</td>
<td>7</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>7</td>
</tr>
<tr>
<td>TABLES</td>
<td></td>
</tr>
<tr>
<td>Characteristics of included studies</td>
<td>9</td>
</tr>
<tr>
<td>Characteristics of excluded studies</td>
<td>15</td>
</tr>
<tr>
<td>ANALYSES</td>
<td>15</td>
</tr>
<tr>
<td>Comparison 01. TENS/AL-TENS vs. placebo</td>
<td>15</td>
</tr>
<tr>
<td>Comparison 02. AL-TENS vs. placebo</td>
<td>15</td>
</tr>
<tr>
<td>Comparison 03. TENS vs. placebo</td>
<td>16</td>
</tr>
<tr>
<td>Comparison 04. TENS vs. placebo, follow up</td>
<td>16</td>
</tr>
<tr>
<td>Comparison 06. TENS vs. placebo, after one application</td>
<td>16</td>
</tr>
<tr>
<td>Comparison 11. Subgroup analysis</td>
<td>16</td>
</tr>
<tr>
<td>INDEX TERMS</td>
<td></td>
</tr>
<tr>
<td>COVER SHEET</td>
<td></td>
</tr>
<tr>
<td>GRAPHS AND OTHER TABLES</td>
<td></td>
</tr>
<tr>
<td>Analysis 01.01. Comparison 01 TENS/AL-TENS vs. placebo, Outcome 01 Pain Relief (VAS)</td>
<td>18</td>
</tr>
<tr>
<td>Analysis 01.02. Comparison 01 TENS/AL-TENS vs. placebo, Outcome 02 Knee stiffness</td>
<td>18</td>
</tr>
<tr>
<td>Analysis 02.01. Comparison 02 AL-TENS vs. placebo, Outcome 01 Pain relief</td>
<td>19</td>
</tr>
<tr>
<td>Analysis 02.02. Comparison 02 AL-TENS vs. placebo, Outcome 02 Stiffness of the knee</td>
<td>19</td>
</tr>
<tr>
<td>Analysis 02.03. Comparison 02 AL-TENS vs. placebo, Outcome 03 50-foot walking time</td>
<td>19</td>
</tr>
<tr>
<td>Analysis 02.04. Comparison 02 AL-TENS vs. placebo, Outcome 04 Quadriceps muscle strength</td>
<td>20</td>
</tr>
<tr>
<td>Analysis 02.05. Comparison 02 AL-TENS vs. placebo, Outcome 05 Knee flexion</td>
<td>20</td>
</tr>
<tr>
<td>Analysis 03.01. Comparison 03 TENS vs. placebo, Outcome 01 Pain Relief (VAS)</td>
<td>21</td>
</tr>
<tr>
<td>Analysis 03.02. Comparison 03 TENS vs. placebo, Outcome 02 Number of patients with pain improvement</td>
<td>21</td>
</tr>
<tr>
<td>Analysis 04.01. Comparison 04 TENS vs. placebo, follow up, Outcome 01 Number of patients with pain improvement</td>
<td>22</td>
</tr>
<tr>
<td>Analysis 06.01. Comparison 06 TENS vs. placebo, after one application, Outcome 01 Pain relief</td>
<td>22</td>
</tr>
<tr>
<td>Analysis 11.01. Comparison 11 Subgroup analysis, Outcome 01 Pain relief (VAS)</td>
<td>23</td>
</tr>
<tr>
<td>Analysis 11.02. Comparison 11 Subgroup analysis, Outcome 02 Pain relief (VAS)</td>
<td>24</td>
</tr>
<tr>
<td>Analysis 11.03. Comparison 11 Subgroup analysis, Outcome 03 Pain relief VAS)</td>
<td>25</td>
</tr>
<tr>
<td>Analysis 11.04. Comparison 11 Subgroup analysis, Outcome 04 Pain relief VAS)</td>
<td>26</td>
</tr>
</tbody>
</table>
Transcutaneous electrical nerve stimulation for knee osteoarthritis (Review)


This record should be cited as:

This version first published online: 23 October 2000 in Issue 4, 2000.
Date of most recent substantive amendment: 30 August 2000

ABSTRACT

Background
Osteoarthritis (OA) is a disease that affects synovial joints causing degeneration and destruction of hyaline cartilage. To date, no curative treatment for OA exists. The primary goals for OA therapy are to relieve pain, maintain or improve functional status, and minimize deformity. Transcutaneous electrical nerve stimulation (TENS) is a noninvasive modality that is commonly used in physiotherapy to control both acute and chronic pain arising from several conditions. A number of trials evaluating the efficacy of TENS in OA have been published.

Objectives
To assess the effectiveness of TENS in the treatment of knee OA, studies of one year or longer were included in the review. The primary outcomes of interest were those described by the Outcome Measures in Rheumatology Clinical Trials (OMERACT 3), which included pain relief, functional status, patient global assessment and change in joint imaging. The secondary objective was to determine the most effective mode of TENS application for pain control.

Search strategy
We searched the Cochrane Controlled Trials Register, MEDLINE, EMBASE, CINAHL, HEALTHSTAR, PEDro and Current Contents (to December 1999) using the Cochrane Musculoskeletal Group search strategy. We also hand-searched reference lists and consulted content experts.

Selection criteria
Two independent reviewers selected the trials that met predetermined inclusion criteria.

Data collection and analysis
Two independent reviewers extracted the data using standardized forms and assessed the quality of studies for randomization, blinding and dropouts. A third reviewer was consulted to resolve any differences. For dichotomous outcomes, relative risks (RR) were calculated. For continuous data, weighted mean differences (WMD) or standardized mean differences (SMD) of the change from baseline were calculated. A fixed effects model was used unless heterogeneity of the populations existed. In this case, a random effects model was used.

Main results
Seven trials were eligible to be included in this review. Six used TENS as the active treatment while one study used acupuncture like TENS (AL-TENS). A total of 148 and 146 patients were involved in the active TENS treatment and placebo groups respectively. Three studies were cross-over studies and the other four were parallel group, randomized controlled trials (RCTs). The median methodological quality of these studies was three out of five. Pain relief from active TENS and AL-TENS treatment was significantly better than placebo treatment. Knee stiffness also improved significantly in the active treatment group compared to placebo. Different modes of TENS settings (high frequency and strong burst mode TENS) all demonstrated a significant benefit in pain relief of the knee OA over placebo. Subgroup analyses showed a heterogeneity in the studies with methodological quality of three or more and those with repeated TENS applications.
Osteoarthritis (OA) is primarily a disease of cartilage as it is characterized by the degradation of hyaline cartilage in the joints (Solomon 1997). It is believed to be a dynamic disease that reflects the balance between destruction and repair (Solomon 1997). The destruction processes of cartilage: softening and fibrillation, exposure of the subarticular bone plate, and fragmentation of the subchondral trabeculae, are accompanied by hyperactive new bone formation, osteophytosis, and bone remodeling (Solomon 1997). OA is the most common form of arthritis and one of the most important causes of long-term disability in adults (Solomon 1997, Peyron 1992). OA has a worldwide distribution though there is a variation in the prevalence among different ethnic groups and genders. However, OA mainly affects the elderly population. The prevalence of OA in populations older than 60 years of age is more than 50% (Solomon 1997). The common sites of joints to develop OA include the knee, hand, hip, spine and foot. Of these, OA of the knee is most commonly found. In addition to increasing age, OA of the knee is associated with obesity, trauma, history of inflammatory arthritis and certain metabolic diseases such as acromegaly and calcium pyrophosphate dihydrate (CPPD) arthropathy (Fife 1997). Common complaints in people with knee OA are pain exacerbated by movement or weight bearing, stiffness, swelling and deformity ( genu varum or genu valgum), and restricted walking distance.

The objectives of management of OA of the knee are to relieve pain, maintain or improve mobility, and minimize disability. Treatment options include non-pharmacologic intervention, drug therapy, and surgery (Fife 1997). Different modalities in physiotherapy have been shown to help improve clinical symptoms and function of knee OA, with fewer adverse effects than medical treatment. Transcutaneous electrical nerve stimulation (TENS) is among these non-invasive therapies.

TENS therapy has been used to treat a variety of painful acute and chronic conditions (Puett 1994, Gersh 1985, Lampe 1978). This neuromodulatory method is based on the 'Gate-Control Theory' of pain perception as described by Melzack and Wall (Melzack 1965). Pain impulses are transmitted to the spinal cord via small cutaneous (delta) fibers. TENS stimulates large cutaneous (beta) fibers that subsequently transmit a faster impulse via C-fibers to inhibit the pain signals from the small fibers. Thus, TENS devices were designed to be used as afferent nerve stimulators that provide adequate pain relief without involving invasive procedures. Several studies have shown that TENS may also stimulate endogenous opiates secretion (Andersson 1976, Grimmer 1992, Mayer 1989). Three important factors that determine the quality of a TENS device include: (1) selection of functioning mode (e.g. stimulators, electrode type, design); (2) the wave form of the device, which is modified by adjusting the amplitude, rate, and width controls; and (3) the proper location of electrodes (Lampe 1978).

Four types of TENS device settings are currently used in clinical practice: 1) high frequency (40 to 150 Hz, 50 to 100 µsec pulse width, moderate intensity); 2) low frequency (1 to 4 Hz, 100 to 400 µsec pulse width, high intensity); 3) burst frequency (1 to 4 Hz with high internal frequency, 100 to 250 µsec pulse width, high intensity); and 4) hyperstimulation (1 to 4 Hz, 10 to 500 msec pulse width, high intensity) (Jette 1986).

The objectives of management of OA of the knee are to relieve pain, maintain or improve mobility, and minimize disability. Treatment options include non-pharmacologic intervention, drug therapy, and surgery (Fife 1997). Different modalities in physiotherapy have been shown to help improve clinical symptoms and function of knee OA, with fewer adverse effects than medical treatment. Transcutaneous electrical nerve stimulation (TENS) is among these non-invasive therapies.

TENS and AL-TENS over at least four weeks are effective for pain control and relief of knee stiffness in osteoarthritis

Transcutaneous electrical nerve stimulation (TENS) is a non-invasive modality with very few adverse effects that is used in physiotherapy for control of pain. Seven studies using TENS in people with knee osteoarthritis (OA) were identified for this review; device setting, application and outcomes measured varied between studies. Active TENS and 'acupuncture like' TENS (AL-TENS) treatment for at least four weeks effectively reduced pain. Knee stiffness also improved significantly. More well designed studies, with a large study population and sufficient intervention period, are needed to determine the overall effectiveness of TENS for the treatment of knee OA.

Authors’ conclusions

TENS and AL-TENS are shown to be effective in pain control over placebo in this review. Heterogeneity of the included studies was observed, which might be due to the different study designs and outcomes used. More well designed studies with a standardized protocol and adequate numbers of participants are needed to conclude the effectiveness of TENS in the treatment of OA of the knee.

**Background**

Osteoarthritis (OA) is primarily a disease of cartilage as it is characterized by the degradation of hyaline cartilage in the joints (Solomon 1997). It is believed to be a dynamic disease that reflects the balance between destruction and repair (Solomon 1997). The destruction processes of cartilage: softening and fibrillation, exposure of the subarticular bone plate, and fragmentation of the subchondral trabeculae, are accompanied by hyperactive new bone formation, osteophytosis, and bone remodeling (Solomon 1997). OA is the most common form of arthritis and one of the most important causes of long-term disability in adults (Solomon 1997, Peyron 1992). OA has a worldwide distribution though there is a variation in the prevalence among different ethnic groups and genders. However, OA mainly affects the elderly population. The prevalence of OA in populations older than 60 years of age is more than 50% (Solomon 1997). The common sites of joints to develop OA include the knee, hand, hip, spine and foot. Of these, OA of the knee is most commonly found. In addition to increasing age, OA of the knee is associated with obesity, trauma, history of inflammatory arthritis and certain metabolic diseases such as acromegaly and calcium pyrophosphate dihydrate (CPPD) arthropathy (Fife 1997). Common complaints in people with knee OA are pain exacerbated by movement or weight bearing, stiffness, swelling and deformity (genu varum or genu valgum), and restricted walking distance.

The objectives of management of OA of the knee are to relieve pain, maintain or improve mobility, and minimize disability. Treatment options include non-pharmacologic intervention, drug therapy, and surgery (Fife 1997). Different modalities in physiotherapy have been shown to help improve clinical symptoms and function of knee OA, with fewer adverse effects than medical treatment. Transcutaneous electrical nerve stimulation (TENS) is among these non-invasive therapies.

TENS and AL-TENS over at least four weeks are effective for pain control and relief of knee stiffness in osteoarthritis

Transcutaneous electrical nerve stimulation (TENS) is a non-invasive modality with very few adverse effects that is used in physiotherapy for control of pain. Seven studies using TENS in people with knee osteoarthritis (OA) were identified for this review; device setting, application and outcomes measured varied between studies. Active TENS and ‘acupuncture like’ TENS (AL-TENS) treatment for at least four weeks effectively reduced pain. Knee stiffness also improved significantly. More well designed studies, with a large study population and sufficient intervention period, are needed to determine the overall effectiveness of TENS for the treatment of knee OA.

**Plaint Language Summary**

TENS and AL-TENS over at least four weeks are effective for pain control and relief of knee stiffness in osteoarthritis

Transcutaneous electrical nerve stimulation (TENS) is a non-invasive modality with very few adverse effects that is used in physiotherapy for control of pain. Seven studies using TENS in people with knee osteoarthritis (OA) were identified for this review; device setting, application and outcomes measured varied between studies. Active TENS and ‘acupuncture like’ TENS (AL-TENS) treatment for at least four weeks effectively reduced pain. Knee stiffness also improved significantly. More well designed studies, with a large study population and sufficient intervention period, are needed to determine the overall effectiveness of TENS for the treatment of knee OA.
- Pulse form (intensity, rate and width);
- Electrode placement site;
- Frequency and duration of treatment.

**Criteria for Considering Studies for This Review**

### Types of studies
Randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that were eligible according to an a priori protocol.

### Types of participants
Only trials with people, aged 18 years or more, with clinical and/or radiological confirmation of OA of the knee were included. Diagnosis of knee OA was defined using the American College of Rheumatology (ACR) criteria of classification of OA of the knee (Altman 1986). No participants had any surgical intervention of the affected knee.

### Types of intervention
All types of TENS were included in this review. Trials that compared TENS intervention with standard treatment and/or placebo were included.

### Types of outcome measures
The primary outcome measure was pain relief, according to the Outcome Measures in Rheumatology Clinical Trials (OMERACT 3) (Bellamy 1997). In addition, the other outcome measures from OMERACT 3 were also included for potential analysis.

OMERACT measures for OA include:
- Pain;
- Physical function;
- Patient global assessment;
- Joint imaging (for studies of one year or longer).

In addition, the outcome measures recommended by Morin and colleagues (Morin 1996) were included. They were:
- Duration of morning stiffness;
- Quadriceps muscle strength;
- Knee range of motion (ROM);
- Knee circumference;
- Walking distance and walking time.

**Search Methods for Identification of Studies**

See: methods used in reviews.

Published clinical trials of TENS for knee OA were identified through a search of the Cochrane Musculoskeletal Group register, Cochrane Controlled Trial Register (CCTR) issue 1, 2000, MEDLINE (1966 to 1999), EMBASE (1975 to 1999), CINAHL, HEALTHSTAR and Physiotherapy Evidence Database (PEDro) using the sensitive search strategy of the Cochrane Musculoskeletal Group based on work by Dickersin 1994 and Haynes 1994.

Reference lists were handsearched for further identification of published work, presentations at scientific meetings and personal communications. Content experts were contacted for additional studies and unpublished data (Dickersin 1997).

The search strategy used for the MEDLINE database is as follows:

1. pain.tw, hw.
2. activities of daily living/
3. (joint$ adj4 (mobility or flexibility)).tw.
4. (return$ adj3 (work or leisure)).tw.
5. (function$ adj2 (status or ability$)).tw.
6. (stiffness or swelling or swollen or tender).tw.
7. (flexion or extension or abduction or adduction).tw.
8. range of motion, articular/
10. (strength or power).tw.
11. (grip$ or force or rotation).tw.
12. (dynamometer$ or goniometer$).tw.
13. absenteeism/ or absenteeism.tw.
14. (sick leave or sick day$ or absence).tw.
15. sick leave/
16. (disability$ or (work$ adj compensation)).tw.
17. cost$.tw.
18. exp economics/ or ec.fs.
19. ar/1-18
20. exp electric stimulation therapy/
21. ((electric$ adj nerve) or therapy).tw.
22. ((electric$ adj (stimulation or muscle)).tw.
23. electrostimulation.tw.
24. electroanalgesia.tw.
25. (tens or alternating).tw.
26. electroacupuncture.tw.
27. neuromuscular$ electric$.tw.
28. (high volt or pulsed or current).tw.
29. (electromagnetic or electrotherapy$).tw.
30. iontophoresis.tw.
31. ar/20-30
32. knee, sh, tw.
33. exp knee joint/
34. osteoarthritis/
35. osteoarthritic.tw.
36. (32 or 33) and (34 or 35)
37. 31 and 36
38. animal/ not (human/ and animal/)
39. 37 not 38
40. randomized controlled trial, pt.
41. controlled clinical trials/
M E T H O D O S O F T H E R E V I E W

The above search strategy identified a set of potentially relevant articles. These trials were assessed by two independent reviewers (LB, MO). Studies were selected for inclusion in the review according to the inclusion criteria.

From each included trial, we collected information regarding the trial design, participant characteristics, dosages i.e. modes of TENS application, treatment periods, baseline and end of study outcomes. Data concerning details of the studied population, intervention and outcomes were extracted by two independent reviewers (LB, MO) using pre-determined extraction forms. Differences in data extraction were resolved by referring back to the original article and establishing consensus. A third reviewer (VW) was consulted to help resolve differences. When necessary, information was sought from the authors of the primary studies.

Where possible, the analyses were based on intention-to-treat data from the individual clinical trials. Subgroup analyses were conducted to examine the efficacy of TENS with different application methods and modes (including frequency, length of treatment and techniques). A sensitivity analysis was conducted based on the methodological quality of each trial.

Statistics analysis
All of the data from the individual trials were entered into a spreadsheet. This spreadsheet provided the data for the Review Manager software (RevMan 4.0), which was used for both descriptive and statistical data. For continuous data, results were presented as a weighted mean difference (WMD). However, where different scales were used to measure the same concept or outcome, standardized mean differences (SMD) were used. For dichotomous data, relative risk (RRs) were used (Petitti 1994, Hennekens 1987). Heterogeneity was calculated using a Chi square test and considered significant when the probability (P-value) was less than 0.05. Fixed effects models were used throughout unless heterogeneity was significant, in which case a random effect model was used. Publication bias was not assessed due to the probable small number of studies.

D E S C R I P T I O N O F S T U D I E S

The search strategies retrieved 210 articles. From these, nine RCTs met the inclusion criteria of which seven studies (294 participants) were included in the meta-analysis. The reasons for not including the other two trials were: only descriptive results were given in one trial (Jensen 91); the device was not considered to be TENS in the other (Zizic 1995).

The included RCTs involved 148 participants in the active TENS treatment and 146 participants in the placebo groups. Three studies were cross-over studies (Taylor 1981, Lewis D 1984, Lewis B 1994), two were randomized single-blind, parallel group studies (Smith 1983, Yurtkuran 1999) and the other two were double-blind, placebo-controlled trials (Fargas-Babjak 1989, Grimmer 1992). Four studies used high frequency mode TENS while the trial by Fargas-Babjak and colleagues (Fargas-Babjak 1989) used strong burst mode TENS. The study by Grimmer 1992 was a three-arm trial comparing the efficacy of high frequency TENS with that of burst mode TENS and placebo. The study by Yurtkuran and Kocagil (1999) was a four-arm study comparing the efficacy of acupuncture like TENS (AL-TENS) to those of electroacupuncture (EA), ice massage and placebo.

All of the participants in the included trials were diagnosed with knee OA based on clinical and/or radiographic evidences. All had painful knee OA that required pharmaceutical intervention. Although the studied population in the included RCTs seemed to be homogeneous, the TENS application protocols were markedly diverse. Differences included the modes of stimulation, optimal stimulation levels, pulse frequencies, electrode placements, lengths of stimulation time and how often TENS was applied. The results of this meta-analysis were stratified by the duration and modes of TENS application. The outcome measures also varied from one study to another.

M E T H O D O L O G I C A L Q U A L I T Y

The quality of the included studies was assessed using a scale developed by Jadad (Jadad 1996, Clark 1999), which included the appropriateness of randomization and of blinding, and consideration of dropouts and withdrawals in statistical analysis.

Quality was assessed independently by two reviewers (LB, MO). Differences were resolved by consensus. A third reviewer (VW) was consulted if necessary. Studies were divided into low and high quality, based on the median quality score, to examine the effect of quality on outcome measures. The maximum quality score was five. Studies with a score less than three were considered low quality.
For the study by Grimmer 1992, we did a separate analysis of two significant while the other was not.

There were only two individual studies for which the results were compared to placebo and expressed as standardized mean difference (SMD) with 95% confidence intervals (CI), pain relief, measured using a visual analogue scale (VAS), improved significantly in the treatment group [SMD -0.448 VAS (95%CI: -0.703 to -0.192)]. There were only two individual studies for which the results were significant, i.e. the study by Fargas-Babjak (Fargas-Babjak 1989) and the AL-TENS study by Yurkuran and Kocagil (Yurkuran 1999). This analysis used the random effects model, due to the heterogeneity of the included trials.

Stiffness of the knee was also improved significantly in the combined TENS/AL-TENS treatment group compared to placebo as shown by the weighted mean difference (WMD) [WMD -5.972 cm (95% CI: -9.89 to -2.055)].

If only the studies of TENS application compared to placebo were analyzed, pain measured on a VAS was still significantly less in the TENS group [SMD -0.38 VAS (95%CI: -0.655 to -0.104)]. The analysis of TENS versus placebo studies still showed heterogeneity. The result was similar when AL-TENS was compared to placebo; the WMD of pain relief was -0.08 cm (95% CI: -1.386 to -0.214) in favour of AL-TENS. The other outcomes: stiffness of the knee [WMD -7.9 cm (95% CI -12.099 to -3.701)], 50-foot walking time [WMD -22.6 minutes (95% CI -43.012 to -2.188)], quadriceps muscle strength [WMD -5.2 kg (95% CI -7.853 to -2.547)], and knee flexion [WMD -11.3 degrees (95% CI -17.592 to -5.008)] were also improved significantly in the AL-TENS group compared to placebo.

The number of participants reporting pain improvement was significantly different between the TENS treated group and placebo group [RR 2.41 (95% CI: 1.58 to 3.69)]. The participants in the TENS treatment group were more than twice more likely to have pain improvement than those in the placebo group. After they finished their courses of TENS treatment, the participants in this group still did better than those in the placebo group regarding pain improvement as shown in follow up studies [RR 2.7 (95%CI: 0.94 to 7.72)]. However, heterogeneity existed in this analysis, which may be explained by the result from one study being significant while the other was not.

For the study by Grimmer 1992, we did a separate analysis of two different kinds of TENS applications compared to placebo. After one application, pain relief with high frequency TENS application was significantly better than placebo [WMD -2.1 cm (95% CI: -4.115 to -0.085)] while the difference in pain relief between strong burst mode TENS and placebo did not reach a significant level [WMD -1.6 cm (95% CI: -3.209 to 0.009)].

Subgroup Analysis:

Methodological quality
The quality scores of the included trials did not exceed 3. Three studies with the quality scores of 1 and 2 were compared to the other four with a score of 3. Heterogeneity was observed in the results from studies with high quality scores. Using a random effects model, pain relief was significantly different from placebo in high quality studies [SMD -0.582 (95% CI: -0.934 to -0.23)] but not in low quality studies (SMD -0.291 (95%CI: -0.654 to 0.072)).

High frequency TENS versus strong burst mode TENS versus AL-TENS

No heterogeneity was found within each mode of TENS setting. However, pain relief by strong burst mode TENS and AL-TENS was approximately two times better than with high frequency TENS. The pain relief when strong burst mode TENS was compared to placebo was [SMD -0.72 (95% CI: -1.183 to -0.256)], when AL-TENS was compared to placebo was [SMD -0.745 (95% CI: -1.32 to -0.171)], and when high frequency TENS was compared to placebo was [SMD -0.332 (95% CI: -0.648 to -0.016)].

Single versus repeated applications
Heterogeneity was observed in the results from studies with repeated TENS applications. Thus, the random effects model was used. Pain relief was not significant in the study with single TENS application [SMD -0.633 cm (95% CI -1.27 to -0.004)] but improved significantly in studies with repeated TENS applications [SMD -0.324 cm (95% CI -0.645 to -0.003)].

Length of duration of TENS application
The duration of TENS application in each session in the included studies ranged from 20 to 60 minutes and the length of the experimental intervention period varied from one treatment session to six week sessions. The efficacy of TENS for pain relief in studies with intervention period less than four weeks was not significantly different from placebo [SMD -0.288 (95%CI: -0.585 to 0.009)]. On the other hand, TENS application for at least four weeks showed a significant efficacy in pain relief compared to placebo [SMD -0.85 (95% CI: -1.527 to -0.174)].

DISCUSSION

Osteoarthritis (OA) is one of the most important causes of chronic pain in the general population (Peyron 1992, Solomon 1997). (Solomon 1997, Peyron 1992) Treatment of pain in patients with OA is mainly with analgesic medications that can cause serious adverse events in long-term use. To avoid the adverse effects from these drugs other modalities have been introduced and
their effectiveness has been demonstrated. TENS is one non-invasive modalities recognised to be helpful in pain control. In addition to OA, TENS has been used to relieve acute and chronic pain caused by various etiologies (Gersh 1985, Lampe 1978, Puett 1994). Studies regarding the use of TENS for pain relief in OA have been conducted but the results are controversial. The objective of this systematic review was to evaluate the efficacy of TENS in the treatment of knee OA.

All of the study participants had OA of one or both knees, diagnosed by clinical symptoms and radiographic evidence, and the OA was painful despite medical treatment. The protocols for TENS device setting and application varied widely between studies, as well as the outcome measures. Study designs included parallel group and cross-over studies. For the cross-over studies, only data from the first intervention was collected in order to eliminate the carry-over effects of earlier interventions. Modes of TENS device settings used in the included trials were conventional (high frequency or strong burst mode) and acupuncture-like TENS. High frequency TENS has been shown to affect the central and peripheral mechanisms of pain control (Melzack 1965, Andersson 1976). Strong burst mode TENS stimulates intrinsic endogenous opiates secretion as well as rhythmic muscle contractions (Lundberg 1984). For AL-TENS, low frequency, high intensity pulses applied to somatic acupuncture points are used (Shealy 1993). AL-TENS has been shown to increase the pain threshold (Yurtkuran 1999).

Pain relief, measured both by using a visual analogue scale (VAS) and the number of participants experiencing pain relief, was significantly different between the TENS and placebo groups. Strong evidence came from the study comparing strong burst mode TENS to placebo, for six weeks, which showed a significant benefit in pain relief from TENS (Fargas-Babjak 1989). This study had a methodological quality score of three and was a double-blind RCT. Thus, the efficacy of TENS from this study was quite acceptable. Other outcomes including ambulation, stiffness, knee circumference and knee range of motion were not significantly different between the treatment and placebo groups. This might be explained by the low methodological quality of the included studies measuring these outcomes, a wide variety of TENS devices used and application protocols, or inadequate intervention periods (short trials). Results from the AL-TENS study, however, showed a promising improvement in all outcomes, at two weeks, compared to placebo. This study was a double-blind RCT with a quality score of three. There has been evidence that the neuroregulatory effects and pain transmission moderation effects of the TENS are more effective with higher intensity application (Langley 1984), such as with the acupuncture-like application. Moreover, AL-TENS might also act in the same manner as traditional acupuncture.

Interestingly, when two different modes of TENS applications were compared to placebo in the study by Grimmer 1992, high frequency TENS reduced the pain significantly but there was no significant difference in pain relief between strong burst mode TENS and placebo. However, in the subgroup analysis when the results of the other studies were pooled, both high frequency and strong burst mode TENS improved pain significantly, and the strong burst mode TENS improved the pain even more than did high frequency TENS. This might be explained by the effects of the other studies, which outweighed the results of the study by Grimmer.

The median and highest quality score of the included studies was three. Three studies had quality scores less than three. The explanation of these low quality scores could be because of the difficulty to perform appropriate randomization or appropriate double blinding. Insufficient information was noted in several RCTs about the treatment assignment procedure. Complete blinding is difficult to achieve due to the sensory differences between treatment and placebo, as well as unintended communication between patient and evaluator (Deyo 1990). A valid placebo in TENS RCTS is difficult to find since TENS involves cutaneous stimulation. Not all studies reported adequate information regarding withdrawals and loss to follow up, nor indicated whether they were considered in the data analysis. These weaknesses contribute to the lower quality assessment scores in this systematic review.

Regarding the other outcome measures of knee OA, there was a large variety in the outcomes used in each of the included studies. Most of them could not be pooled. Only stiffness of the knee could be pooled and the pooled estimate was significant in the combined TENS/AL-TENS group.

Although the included trials were all published articles, the number of trials with nonsignificant results (four) was comparable to those with significant results (three). A funnel plot, to test the impact of publication bias on the results, was not performed since the number of the included trials was not large enough to do so. The participants enrolled were those with a definite diagnosis of OA but heterogeneity in the disease (e.g. stage and severity of knee OA) and the people (e.g. lifestyle, co-morbid diseases and concomitant medication) might exist; detailed information on demographic data was incomplete. Variations in the studied participants might, therefore, affect the study results.

No side effect of the TENS treatment was reported in the included trials. This might be because of the relative safety of the TENS, which could be an advantage over the use of analgesic medication.

Subgroup analyses of different frequencies of TENS application and methodological quality showed heterogeneity, in the results from studies with repeated TENS administration and those with quality scores of three or higher. After an appropriate statistical calculation adjustment, a significant difference in pain relief was observed in the studies with higher methodological quality, both modes of TENS device settings, repeated TENS application, and an intervention period of TENS application of at least four weeks.
AUTHORS’ CONCLUSIONS

Implications for practice

Both high frequency and strong burst mode TENS showed a significant benefit on pain relief in the treatment of knee OA. However, when stratified by intervention period, TENS treatment did not show a significant efficacy in pain relief over placebo if the treatment duration was less than four weeks. Only a randomized, double-blind, placebo controlled trial with treatment duration of six weeks has shown that TENS can significantly improve pain relief compared to placebo. A two week study has shown that the AL-TENS is effective in pain relief, decreasing stiffness and walking time, improving quadriceps muscle strength and knee flexion compared with placebo. Subgroup analyses have shown that heterogeneity does exist in the results from studies with different methodological quality scores and different administrations of TENS. TENS may be used as an alternative for pain relief in OA of the knee due to its non-invasive application and few adverse events.

Implications for research

Better study designs are needed to conclude the efficacy of TENS in the treatment of knee OA. The studies should be two-arm, randomized, double-blind, placebo controlled trials with an intervention period long enough to detect a difference (at least six weeks). A regulated study protocol should be developed to standardize the TENS setting, electrode placement and duration of application. The outcome measures should be standardized and contain appropriate subjective and objective outcomes. These will make the studies more reliable and comparable.

POTENTIAL CONFLICT OF INTEREST

None known.

ACKNOWLEDGEMENTS

The authors would like to thank the Cochrane Musculoskeletal editorial team for their valuable comments and Candyce Hamel for her technical support. The authors would also like to thank Janet Wales and Ashley Nicholson for their editorial assistance.

SOURCES OF SUPPORT

External sources of support

- No sources of support supplied

Internal sources of support

- University of Ottawa, Institute of Population Health CANADA
- Ottawa Health Research Institute CANADA
- Faculty of Medicine, Chulalongkorn University, Bangkok THAILAND

REFERENCES

References to studies included in this review

Fargas-Babjak 1989 (published data only)

Grimmer 1992 (published data only)

Lewis B 1994 (published data only)

Lewis D 1984 (published data only)

Smith 1983 (published data only)

Taylor 1981 (published data only)

Yurtkuran 1999 (published data only)

References to studies excluded from this review

Jensen JE 1985

Transcutaneous electrical nerve stimulation for knee osteoarthritis (Review)

Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Lundeberg 1984

Sternbach 1976

Zizic 1995

References to studies awaiting assessment


Additional references
Altman 1986

Andersson 1976

Bellamy 1997

Clark 1999

Deyo 1990

Dickersin 1994

Dickersin 1997

Fife 1997

Gersh 1985

Haynes 1994

Hennekens 1987

Jadad 1996
Jadad AR, Moore RA, Carrol D. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1–12.

Jette 1986

Lampe 1978

Langley 1984

Lundberg 1984

Mayer 1989

Melzack 1965

Moher 1998

Morin 1996

Petitti 1994
Petitti D. In: Meta-analysis, decision analysis, and cost-effectiveness analysis: method for quantitative synthesis in medicine. 90–114.

Peyron 1992
Puett 1994

Schulz 1995

Shealy 1993

Solomon 1997

* Indicates the major publication for the study

**T A B L E S**

**Characteristics of included studies**

<table>
<thead>
<tr>
<th>Study</th>
<th>Fargas-Babjak 1989</th>
</tr>
</thead>
</table>
| **Methods** | Randomized, double-blind, controlled trial  
Sample size at entry: 56  
Dropouts: 19 in both groups  
Treatment duration: 6 weeks  
Follow up: 3 months |
| **Participants** | Patients with painful OA hip and knee for > 6 months  
No change in their medication  
Exclude: patients involved in legal litigation, were pregnant, had a pacemaker, on glucocorticoid, change their medication within 3 months, failed to answer the questionnaires in a consistent manner  
Age: 29-81 years  
Gender not available  
Patients completed the study: 37 (19 in treatment group, 18 in placebo group) |
| **Interventions** | TENS:  
schedule: 30 minutes, twice daily for 6 weeks. The first 2 treatments were performed in the clinic by a trained nurse.  
waveform: square pulses  
pulse frequency: 4 Hz and the burst frequency at 200 Hz for 125 ms length  
current: to make a tingling sensation  
electrode placement: on different 13 areas on the acupuncture and tender points of hip and knee  
Placebo: same with a frequency of 0.2 Hz with a threshold electrical stimulus of 0.5 mA |
| **Outcomes** | At 6 weeks: number of patients with  
1) improvement of VAS pain scale > 25%  
2) improvement of West Haven Yale Scale of pain > 1.0 unit |
Characteristics of included studies (Continued)

3) improvement of functional status, goniometry of knee and hip, knee circumference, 50-foot walking time, and tenderness of joint and soft tissue

At 3 months: telephone inquiry of the patient global assessment

| Notes | Quality = 3  
|       | (R1, D1, W1) |
| Allocation concealment | B – Unclear |

Study  | Grimmer 1992 |
---|---|
Methods | Randomized, double-blind, controlled trial with active and placebo comparators |
Sample size at entry: 60 (20 in each group) |
No dropouts reported |
Treatment duration: once for 30 minutes |
Follow up: immediate after treatment |
Participants | Patients who had knee pain from OA with radiologic diagnosis for => 6 months, withhold all analgesics, muscle relaxants, and NSAIDs => 48 hours before the test, never been on TENS, can complete absolute VAS, on hearing aid or cardiac pacemaker, and physically fit enough. If had bilateral knee pain, would consider only the most painful knee. |
Male/female: 7/13, 8/12, 8/12 |
Mean (SD) age: 65.6 (16.2), 65.7 (16.5), 68.4 (11.3) |
Mean (SD) OA duration: 5.6 (6.6), 9.9 (10.5), 7.9 (9.0) |
Interventions | TENS device: MEDTRONIC NEUROMED SELECTRA |
Electrodes: 4 carbon/rubber/silicone electrodes |
size 2x3 cm. |
Electrode placement: 4 acupuncture points around the knee: medial (spleen 9), lateral (gall bladder 33), posterior (urinary bladder 40), anterior (spleen 10) |
Skin preparation: wash skin around the knee with warm water and soap, rinse with warm water and dry with towels |
Gel: thin coat of Sealsystems Gel (Page Medical) |
Treatment time: 30 minutes once |
Stimulation mode: |
Group 1: conventional High Rate TENS with current of 80 Hz |
Group 2: strong Burst Mode TENS with current of 3 Hz trains of seven 80 Hz pulses |
Placebo: same device with non-functioning electrodes |
Outcomes | 1) Immediate pain relief (vertical absolute VAS) in cm. |
2) Length of pain relief in hours |
3) Immediate stiffness measurement (AVAS) in cm. |
4) Length of stiffness relief in hours |
5) Knee circumference in cm. |
6) knee range of motion (using goniometer) |
Notes | Quality = 2  
|       | (R2, D0, W0) |
Allocation concealment | B – Unclear |

Study  | Lewis B 1994 |
---|---|
Methods | Randomized, crossover placebo controlled trial |
Sample size at entry: 36 in all 3 groups |
### Characteristics of included studies (Continued)

| Dropouts: 10  |
| Treatment duration: 9 weeks (3 weeks for each treatment)  |

**Participants**

Patients with knee OA diagnosed by clinical and radiological evidence with pain at rest for => 6 months. If bilateral, only the more painful knee was chosen. Previous medication for knee pain was abruptly stopped before treatment started.

Number of patients finished this study: 26
Male/female: 15/21
Mean (SD) age: 66 (9.6), range 31-83 years

**Interventions**

Patients were assigned to receive 3 random sequences of 3 interventions:
1) TENS + drug placebo (AT)
2) naprosyn 250 mg bid + placebo TENS (AD)
3) placebo for both (PP)

TENS device: 3M Tenzcare dual-channel stimulators
Wave form: not available
Pulse width: 100 microS
Pulse frequency: 70
Amplitude: adjusted by the patients to reach the highest amplitude consistent with continuous comfort
Electrode placement: 4 acupuncture points: spleen 9, 10 and stomach 34, 35

Placebo: TENS device with an adaptor placed at the end of electrodes to prevent the current flow.
Schedule: 30-60 minutes per session for => 3 sessions per day, continuously for 3 weeks

**Outcomes**

1) Patient's opinion of treatment efficacy (OTE)
2) VAS for pain relief
3) Pain index for the knee (PIK)
4) Daily VAS for pain (DVA)
5) Piper pain intensity scale (PPS)

**Notes**

Quality = 1
(R1, D0, W0)

**Allocation concealment**

B – Unclear

### Study

**Lewis D 1984**

**Methods**

Randomized, double-blind, placebo controlled, crossover trial

Sample size at entry: 30
Dropouts: 2
Treatment duration: 6 weeks (3 weeks in each treatment)

**Participants**

Adult patients with definite diagnosis of knee OA with chronic knee pain for => 12 months

Male/female: 8/22
Median age: 61 years (range 40-83)
Median disease duration: 7.5 years (1-40)

**Interventions**

First "wash out" week: paracetamol only

TENS device: portable, battery-operated RDG Tiger Pulse Stimulator
Stimulation mode: conventional
4 siliconised rubber electrodes
Electrode placement: around the painful knee at Chinese acupuncture points

Placebo: broken contact at the jack-plug of electrode leads
Treated time per session: 30-60 minutes
Schedule of treatment: 3 times a day for 3 weeks
Characteristics of included studies (Continued)

Total number of treatment sessions: 63

Outcomes
1) Pain relief (VAS)
2) Return count of paracetamol tablets
3) Duration of pain relief following each TENS treatment
4) Patient’s opinions questionnaire
5) Pain index

Notes
Quality = 3
(R1, D1, W1)

Allocation concealment
B – Unclear

Study
Smith 1983

Methods
Randomized, single-blind, parallel, placebo controlled trial
Sample size at entry: 32
Dropouts: 2
Number of patients in each group: 15
Treatment duration: 4 weeks
Follow up: at week 4 and 8

Participants
Patients with clinical diagnosis of OA with inclusion criteria:
1) OA knee is the only reason for referral to the physiotherapy department and the only source of pain
2) Age between 50 and 80 years
3) Receive no treatment for OA other than oral analgesics or NSAIDs for 2 months or less
4) No history of malignancy, inflammatory arthropathy, or knee operation
5) No cardiac pacemaker
6) No previous TENS treatment
Male/female: 5/10, 5/10
Mean age in years (range): 65 (50-80), 70 (55-79)

Interventions
First ‘standard’ week without any treatment
Treatment group: TENS device: Battery powered RDG Tiger Pulse
Wave form: square
Conventional mode
Frequency: 32-50 Hz
Pulse width: 80 microsecs
Intensity and voltage control: adjusted until a comfortable tingling sensation is felt
Electrodes: 4
Electrode placements: on tender points around the knee and/or acupuncture points (spleen 9, xiyan and urinary bladder 40)
Electrode jelly: Lectec pads
Placebo: same device with a broken connection between the machine and electrodes at the output jack plug. A 5-10 Hz flashing red light at the device is used for visual reinforcement.
Treatment duration: 20 minutes
Number of sessions: 8 over 4 weeks

Outcomes
'Significant pain relief' defined as
1) Either a ten-point or 50% decrease in weekly pain score, measured on a seven-point daily pain scale, compared with the 'standard' week (max score 49, min 7)
2) A 50% decrease in analgesic intake compared with the 'standard' week.
3) A five-point improvement in the weekly sleep disturbance score, measured on a seven-point weekly scale, compared with the 'standard' week.
Characteristics of included studies (Continued)

If any two of these criteria are fulfilled and no worsening in the other, this means the patient benefits from treatment.
If criteria 1 or 3 is fulfilled alone, and no worsening in any of the criteria, this also means the patient benefits from the treatment.

Number of patients with significant pain relief at end point, at 8 weeks and immediate pain relief.

Notes  
Quality = 3  
(R2, D0, W1)

Allocation concealment  
A – Adequate

Study  
Taylor 1981

Methods  
Randomized, double-blind, crossover, placebo controlled trial
Sample size at entry: 12  
Dropouts: 2  
Study duration: 1 month  
Follow up: 1 year

Participants  
Patients with clinical and radiological evidences of symptomatic knee OA with disability and were candidates for total knee replacement.
If had bilateral knee OA, the more symptomatic knee was chosen to study.
Exclusion: patients who did not complete the study, or with secondary cause of OA  
Male/female: 1/9  
Mean age: 71.5 years  
Mean duration of disease: not available

Interventions  
TENS device: standard dual output Gatron stimulators  
Wave form: not available  
Current, amplitude, and pulse width: adjusted by the patients to produce a "comfortable, firm, tingling" sensation by adjusting the amplitude first, then the pulse width and then the rate.
Electrode placement: 1 each on the anterior, posterior, lateral, and medial sided of the painful knee
Placebo: same devices with broken wires and an audio device with the arbitrary setting of the sound at voltage amplitude 7 and adjustable for a pleasant feeling.
Treated time per session: 30-60 minutes  
Schedule of treatment: many times a day for 2 weeks

Outcomes  
1) Subjective pain  
0=no change in pain  
+1=some pain relief  
+2=marked pain relief  
+3=complete pain relief  
-1= pain worse
2) Pain score  
0=no change  
+1= pain improved by one degree in scale  
+2=pain improved by two degrees  
-1=pain worse by one degree
3) Ambulation
Characteristics of included studies (Continued)

- 1=walking less distance
- 4) Pain medication
  0=no change
  +1=taking less medication for pain
  +2=taking no medication
  -1=taking more medication

Notes Quality = 2
(R1,D0,W1)

Allocation concealment B – Unclear

---

Study  | Yurtkuran 1999
---|---

Methods | Randomized, double-blind, parallel group, placebo controlled trial
(double blind for AL-TENS vs placebo, for the other interventions, only single blinded.)
Sample size at entry: 100
Dropouts:0
Number of patients in each group: 25
Treatment duration: 2 weeks
Follow up: at week 2

Participants | Patients who fulfilled the following criteria:
1) duration of knee pain => 6 months
2) osteoarthritic radiological findings
3) no gross leg malalignment
4) no mechanical block to knee motion
5) no significant concomitant medical problem or bleeding tendency
6) not undergoing any specific medical or surgical treatment, or physical therapy
7) no cardiac pacemaker
If both knees were equally painful, the right knee was chosen to study.

Male/female: 9/91 (2/23, 4/21, 0/25, 3/22)
Range of age 45-70 (45-70, 45-69, 45-69, 45-69)
Disease duration: <1 to 40 years

Interventions | Four parallel groups:
1) TENS
device: MEATENS with point detector model F-2
mode of stimulation: low frequency, high intensity, acupuncture-like TENS (AL-TENS) wave form: rectangular
amplitude: 0.4 - 2.5 Volt, the current were increased to create muscle contraction but just below the pain tolerance threshold.
pulse width: 1000 microsecs.
pulse frequency: 4 Hz
dual channel
4 rubber electrodes
placement: SP-9, GB-34, ST-34, ST-35
2) Electroacupuncture (EA)
four stainless acupuncture needles (Seirin: 0.25x40mm) were inserted on pre-sterilized skin at the same four points as AL-TENS. Then the needles were connected to electrostimulator device with same settings.
3) Ice massage: a 10-cm piece of wood with a cube-shaped sponge attached at one end was dipped into the water and then frozen, then used to massage the four acupoints. If the patients experienced pain, treatment would be withheld for 3 minutes.

4) Placebo: used the same device as TENS but with a disconnected jack-plug. A glowing red light on the device was used instead.

treatment time per session: 20 minutes
schedule of treatment: once daily, five days a week for 2 weeks
total number of treatment sessions: 10

Outcomes

1) Present Pain Intensity (PPI): overall pain intensity was measured on a 1-5 scale,
mild = 1
moderate = 2
severe = 3
very severe = 4
excruciating = 5

2) Stiffness
3) 50-foot walking time in minutes
4) Quadriceps muscle strength
5) Active knee flexion

Notes
Quality = 3
(R1, D1, W1)

Characteristics of excluded studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jensen JE 1985</td>
<td>Populations have post-knee surgery conditions.</td>
</tr>
<tr>
<td>Lundeberg 1984</td>
<td>Patients with myalgia, not OA.</td>
</tr>
<tr>
<td>Sternbach 1976</td>
<td>Population have mostly low back pain.</td>
</tr>
<tr>
<td>Zizic 1995</td>
<td>The device used was not considered a TENS device.</td>
</tr>
</tbody>
</table>

ANALYSES

Comparison 01. TENS/AL-TENS vs. placebo

<table>
<thead>
<tr>
<th>Outcome title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Pain Relief (VAS)</td>
<td>6</td>
<td>264</td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>-0.79 [-1.27, -0.30]</td>
</tr>
<tr>
<td>02 Knee stiffness</td>
<td>2</td>
<td>90</td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>-6.02 [-9.07, -2.96]</td>
</tr>
</tbody>
</table>

Comparison 02. AL-TENS vs. placebo

<table>
<thead>
<tr>
<th>Outcome title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Pain relief</td>
<td>1</td>
<td>50</td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>-0.80 [-1.39, -0.21]</td>
</tr>
<tr>
<td>02 Stiffness of the knee</td>
<td>1</td>
<td>50</td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>-7.90 [-11.18, -4.62]</td>
</tr>
<tr>
<td>03 50-foot walking time</td>
<td>1</td>
<td>50</td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>-22.60 [-43.01, -2.19]</td>
</tr>
<tr>
<td>04 Quadriceps muscle strength</td>
<td>1</td>
<td>50</td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>-5.20 [-7.85, -2.55]</td>
</tr>
</tbody>
</table>
Comparison 03. TENS vs. placebo

<table>
<thead>
<tr>
<th>Outcome title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Pain Relief (VAS)</td>
<td>5</td>
<td>214</td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>-0.75 [-1.63, 0.12]</td>
</tr>
<tr>
<td>02 Number of patients with pain improvement</td>
<td>5</td>
<td>201</td>
<td>Peto Odds Ratio 95% CI</td>
<td>3.91 [2.13, 7.17]</td>
</tr>
</tbody>
</table>

Comparison 04. TENS vs. placebo, follow up

<table>
<thead>
<tr>
<th>Outcome title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Number of patients with pain improvement</td>
<td>2</td>
<td>62</td>
<td>Peto Odds Ratio 95% CI</td>
<td>4.31 [1.55, 12.01]</td>
</tr>
</tbody>
</table>

Comparison 06. TENS vs. placebo, after one application

<table>
<thead>
<tr>
<th>Outcome title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Pain relief</td>
<td></td>
<td></td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>Subtotals only</td>
</tr>
</tbody>
</table>

Comparison 11. Subgroup analysis

<table>
<thead>
<tr>
<th>Outcome title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Pain relief (VAS)</td>
<td></td>
<td></td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>Subtotals only</td>
</tr>
<tr>
<td>02 Pain relief (VAS)</td>
<td></td>
<td></td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>Subtotals only</td>
</tr>
<tr>
<td>03 Pain relief VAS</td>
<td></td>
<td></td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>Subtotals only</td>
</tr>
<tr>
<td>04 Pain relief VAS</td>
<td></td>
<td></td>
<td>Weighted Mean Difference (Fixed) 95% CI</td>
<td>Subtotals only</td>
</tr>
</tbody>
</table>

INDEX TERMS

Medical Subject Headings (MeSH)
Osteoarthritis, Knee [*therapy]; Outcome Assessment (Health Care); Randomized Controlled Trials; Transcutaneous Electric Nerve Stimulation [*methods]

MeSH check words
Humans

COVER SHEET

Title
Transcutaneous electrical nerve stimulation for knee osteoarthritis

Authors

Contribution of author(s)
Manathip Osiri extracted and analyzed data and wrote the manuscript. Lucie Brosseau and Vivian Welch extracted data and edited early versions of the manuscript. George Wells, Beverley Shea and Peter Tugwell contributed methodological expertise, content and editorial comments for the final drafts. Jessie McGowan designed and conducted the electronic search strategy.
Issue protocol first published /

Review first published /

Date of most recent amendment 10 March 2006

Date of most recent SUBSTANTIVE amendment 30 August 2000

What's New Information not supplied by author

Date new studies sought but none found Information not supplied by author

Date new studies found but not yet included/excluded Information not supplied by author

Date new studies found and included/excluded Information not supplied by author

Date authors’ conclusions section amended Information not supplied by author

Contact address Dr Manathip Osiri
Associate Professor, Division of Rheumatology
Department of Medicine,
Faculty of Medicine
Chulalongkorn University
1873 Rama IV Road, Pathumwan
Bangkok
10330
THAILAND
E-mail: Manathip.O@chula.ac.th
Tel: +662-256-4526
Fax: +662-252-8467

DOI 10.1002/14651858.CD002823

Cochrane Library number CD002823

Editorial group Cochrane Musculoskeletal Group

Editorial group code HM-MUSKEL
### Analysis 01.01. Comparison 01 TENS/AL-TENS vs. placebo, Outcome 01 Pain Relief (VAS)

**Review:** Transcutaneous electrical nerve stimulation for knee osteoarthritis  
**Comparison:** 01 TENS/AL-TENS vs. placebo  
**Outcome:** 01 Pain Relief (VAS)

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight (%)</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>95% CI</td>
</tr>
<tr>
<td>Fargas-Babjak 1989</td>
<td>18</td>
<td>10.72 (64.11)</td>
<td>19</td>
<td>56.05 (37.51)</td>
<td>0.0</td>
</tr>
<tr>
<td>Grimmer 1992</td>
<td>20</td>
<td>2.80 (3.20)</td>
<td>20</td>
<td>4.90 (3.30)</td>
<td>5.8</td>
</tr>
<tr>
<td>Lewis B 1994</td>
<td>31</td>
<td>43.20 (23.10)</td>
<td>28</td>
<td>48.10 (28.60)</td>
<td>0.1</td>
</tr>
<tr>
<td>Lewis D 1984</td>
<td>29</td>
<td>4.80 (2.45)</td>
<td>29</td>
<td>5.50 (2.45)</td>
<td>14.9</td>
</tr>
<tr>
<td>Taylor 1981</td>
<td>10</td>
<td>0.90 (1.90)</td>
<td>10</td>
<td>0.80 (1.60)</td>
<td>10.0</td>
</tr>
<tr>
<td>Yurtkuran 1999</td>
<td>25</td>
<td>0.20 (0.89)</td>
<td>25</td>
<td>1.00 (1.20)</td>
<td>69.1</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>133</td>
<td></td>
<td>131</td>
<td></td>
<td>100.0</td>
</tr>
</tbody>
</table>

Test for heterogeneity chi-square=9.85 df=5 p=0.08 I² =49.3%  
Test for overall effect z=3.16 p=0.002

#### Analysis 01.02. Comparison 01 TENS/AL-TENS vs. placebo, Outcome 02 Knee stiffness

**Review:** Transcutaneous electrical nerve stimulation for knee osteoarthritis  
**Comparison:** 01 TENS/AL-TENS vs. placebo  
**Outcome:** 02 Knee stiffness

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight (%)</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>95% CI</td>
</tr>
<tr>
<td>Grimmer 1992</td>
<td>20</td>
<td>3.00 (6.40)</td>
<td>20</td>
<td>6.90 (7.90)</td>
<td>47.0</td>
</tr>
<tr>
<td>Yurtkuran 1999</td>
<td>25</td>
<td>0.60 (5.87)</td>
<td>25</td>
<td>8.50 (8.96)</td>
<td>53.0</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>45</td>
<td></td>
<td>45</td>
<td></td>
<td>100.0</td>
</tr>
</tbody>
</table>

Test for heterogeneity chi-square=1.64 df=1 p=0.20 I² =39.0%  
Test for overall effect z=3.86 p=0.0001
### Analysis 02.01. Comparison 02 AL-TENS vs. placebo, Outcome 01 Pain relief

Review: Transcutaneous electrical nerve stimulation for knee osteoarthritis

Comparison: 02 AL-TENS vs. placebo

Outcome: 01 Pain relief

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>AL-TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>(%)</td>
</tr>
<tr>
<td>Yurtkuran 1999</td>
<td>25</td>
<td>25</td>
<td>0.20 (0.89)</td>
<td>1.00</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>25</td>
<td>25</td>
<td>-0.80 [-1.39, -0.21]</td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity: not applicable
Test for overall effect z=2.68 p=0.007

---

### Analysis 02.02. Comparison 02 AL-TENS vs. placebo, Outcome 02 Stiffness of the knee

Review: Transcutaneous electrical nerve stimulation for knee osteoarthritis

Comparison: 02 AL-TENS vs. placebo

Outcome: 02 Stiffness of the knee

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>AL-TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>(%)</td>
</tr>
<tr>
<td>Yurtkuran 1999</td>
<td>25</td>
<td>25</td>
<td>0.60 (5.87)</td>
<td>8.50</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>25</td>
<td>25</td>
<td>-7.90 [-11.18, -4.62]</td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity: not applicable
Test for overall effect z=4.72 p<0.00001

---

### Analysis 02.03. Comparison 02 AL-TENS vs. placebo, Outcome 03 50-foot walking time

Review: Transcutaneous electrical nerve stimulation for knee osteoarthritis

Comparison: 02 AL-TENS vs. placebo

Outcome: 03 50-foot walking time

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>AL-TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>(%)</td>
</tr>
<tr>
<td>Yurtkuran 1999</td>
<td>25</td>
<td>25</td>
<td>5.60 (5.30)</td>
<td>28.20</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>25</td>
<td>25</td>
<td>-22.60 [-43.01, -2.19]</td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity: not applicable
Test for overall effect z=2.17 p=0.03
Analysis 02.04. Comparison 02 AL-TENS vs. placebo, Outcome 04 Quadriceps muscle strength

Review: Transcutaneous electrical nerve stimulation for knee osteoarthritis
Comparison: 02 AL-TENS vs. placebo
Outcome: 04 Quadriceps muscle strength

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>AL-TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>95% CI</td>
<td>(%)</td>
<td>95% CI</td>
</tr>
<tr>
<td>Yurtkuran 1999</td>
<td>25</td>
<td>-4.40 (6.40)</td>
<td></td>
<td>100.0</td>
<td>-5.20 (-7.85, -2.55)</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>25</td>
<td>25</td>
<td>-5.20 (-7.85, -2.55)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity: not applicable
Test for overall effect: z=3.84 p=0.0001

Analysis 02.05. Comparison 02 AL-TENS vs. placebo, Outcome 05 Knee flexion

Review: Transcutaneous electrical nerve stimulation for knee osteoarthritis
Comparison: 02 AL-TENS vs. placebo
Outcome: 05 Knee flexion

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>AL-TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>95% CI</td>
<td>(%)</td>
<td>95% CI</td>
</tr>
<tr>
<td>Yurtkuran 1999</td>
<td>25</td>
<td>-2.40 (11.70)</td>
<td></td>
<td>100.0</td>
<td>-11.30 (-17.59, -5.01)</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>25</td>
<td>25</td>
<td>-11.30 (-17.59, -5.01)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity: not applicable
Test for overall effect: z=3.52 p=0.0004
### Analysis 03.01. Comparison 03 TENS vs. placebo, Outcome 01 Pain Relief (VAS)

**Review:** Transcutaneous electrical nerve stimulation for knee osteoarthritis  
**Comparison:** 03 TENS vs. placebo  
**Outcome:** 01 Pain Relief (VAS)

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>TENS Mean(SD)</th>
<th>placebo Mean(SD)</th>
<th>Weight</th>
<th>95% CI</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fargas-Babjak 1989</td>
<td>18</td>
<td>10.72 (64.11)</td>
<td>19</td>
<td>0.1</td>
<td>-45.33 [ -79.41, -11.25 ]</td>
<td></td>
</tr>
<tr>
<td>Grimmer 1992</td>
<td>20</td>
<td>2.80 (3.20)</td>
<td>20</td>
<td>18.9</td>
<td>-2.10 [-4.11, -0.09 ]</td>
<td></td>
</tr>
<tr>
<td>Lewis B 1994</td>
<td>31</td>
<td>43.20 (23.10)</td>
<td>28</td>
<td>0.4</td>
<td>-4.90 [-18.25, 8.45 ]</td>
<td></td>
</tr>
<tr>
<td>Lewis D 1984</td>
<td>29</td>
<td>4.80 (2.45)</td>
<td>5.50 (2.45)</td>
<td>48.2</td>
<td>-0.70 [ -1.96, 0.56 ]</td>
<td></td>
</tr>
<tr>
<td>Taylor 1981</td>
<td>10</td>
<td>0.90 (1.90)</td>
<td>10</td>
<td>32.4</td>
<td>0.10 [-1.44, 1.64 ]</td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity chi-square=9.85 df=4 p=0.04 I² =59.4%  
Test for overall effect z=1.69  p=0.09

### Analysis 03.02. Comparison 03 TENS vs. placebo, Outcome 02 Number of patients with pain improvement

**Review:** Transcutaneous electrical nerve stimulation for knee osteoarthritis  
**Comparison:** 03 TENS vs. placebo  
**Outcome:** 02 Number of patients with pain improvement

<table>
<thead>
<tr>
<th>Study</th>
<th>TENS n/N</th>
<th>placebo n/N</th>
<th>Peto Odds Ratio 95% CI</th>
<th>Weight</th>
<th>Peto Odds Ratio 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lewis B 1994</td>
<td>7/29</td>
<td>2/29</td>
<td>3.64 [0.89, 14.91]</td>
<td>18.5</td>
<td></td>
</tr>
<tr>
<td>Lewis D 1984</td>
<td>12/28</td>
<td>4/28</td>
<td>3.96 [1.25, 12.48]</td>
<td>27.8</td>
<td></td>
</tr>
<tr>
<td>Taylor 1981</td>
<td>6/10</td>
<td>5/10</td>
<td>1.47 [0.26, 8.18]</td>
<td>12.5</td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity chi-square=1.76 df=4 p=0.78 I² =0.0%  
Test for overall effect z=4.41  p=0.00001
### Analysis 04.01. Comparison 04 TENS vs. placebo, follow up, Outcome 01 Number of patients with pain improvement

Review: Transcutaneous electrical nerve stimulation for knee osteoarthritis
Comparison: 04 TENS vs. placebo, follow up
Outcome: 01 Number of patients with pain improvement

<table>
<thead>
<tr>
<th>Study</th>
<th>TENS n/N</th>
<th>placebo n/N</th>
<th>Peto Odds Ratio 95% CI (%)</th>
<th>Weight (%)</th>
<th>Peto Odds Ratio 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fargas-Babjak 1989</td>
<td>9/15</td>
<td>2/17</td>
<td></td>
<td>50.7</td>
<td>7.94 [ 1.88, 33.46 ]</td>
</tr>
<tr>
<td>Smith 1983</td>
<td>7/15</td>
<td>4/15</td>
<td></td>
<td>49.3</td>
<td>2.30 [ 0.53, 9.90 ]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>30/32</td>
<td>32</td>
<td></td>
<td>100.0</td>
<td>4.31 [ 1.55, 12.01 ]</td>
</tr>
</tbody>
</table>

Total events: 16 (TENS), 6 (placebo)
Test for heterogeneity chi-square=1.40 df=1 p=0.24 I² =28.7%
Test for overall effect z=2.79 p=0.005

### Analysis 06.01. Comparison 06 TENS vs. placebo, after one application, Outcome 01 Pain relief

Review: Transcutaneous electrical nerve stimulation for knee osteoarthritis
Comparison: 06 TENS vs. placebo, after one application
Outcome: 01 Pain relief

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo Mean(SD)</th>
<th>TENS Mean(SD)</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight (%)</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>01 Strong Burst Mode TENS vs. Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grimmer 1992</td>
<td>20 2.80 (3.20)</td>
<td>20 4.40 (1.80)</td>
<td></td>
<td>100.0</td>
<td>-1.60 [ -3.21, 0.01 ]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>20</td>
<td>20</td>
<td></td>
<td>100.0</td>
<td>-1.60 [ -3.21, 0.01 ]</td>
</tr>
</tbody>
</table>
| Test for heterogeneity: not applicable
| Test for overall effect z=1.95 p=0.05
| 02 High Rate TENS vs. Placebo | | | | | |
| Grimmer 1992   | 20 2.80 (3.20)   | 20 4.90 (3.30) |                                | 100.0      | -2.10 [ -4.11, -0.09 ]          |
| Subtotal (95% CI)  | 20        | 20          |                                | 100.0      | -2.10 [ -4.11, -0.09 ]          |
| Test for heterogeneity: not applicable
| Test for overall effect z=2.04 p=0.04
### Analysis 11.01. Comparison 11 Subgroup analysis, Outcome 01 Pain relief (VAS)

**Review:** Transcutaneous electrical nerve stimulation for knee osteoarthritis  
**Comparison:** 11 Subgroup analysis  
**Outcome:** 01 Pain relief (VAS)

<table>
<thead>
<tr>
<th>Study</th>
<th>placebo</th>
<th>TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight (%)</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>N Mean(SD)</td>
<td>95% CI</td>
</tr>
<tr>
<td>01 study quality &lt; 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grimmer 1992</td>
<td>20</td>
<td>2.80 (3.20)</td>
<td>20</td>
<td>4.90 (3.30)</td>
<td>-2.10 [ -4.11, -0.09 ]</td>
</tr>
<tr>
<td>Lewis B 1994</td>
<td>31</td>
<td>43.20 (23.10)</td>
<td>28</td>
<td>48.10 (28.60)</td>
<td>-4.90 [-18.25, 8.45 ]</td>
</tr>
<tr>
<td>Taylor 1981</td>
<td>10</td>
<td>0.90 (1.90)</td>
<td>10</td>
<td>0.80 (1.60)</td>
<td>0.10 [-1.44, 1.64 ]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>61</td>
<td>58</td>
<td></td>
<td></td>
<td>-0.75 [-1.96, 0.47 ]</td>
</tr>
<tr>
<td><strong>Test for heterogeneity</strong></td>
<td>chi-square=3.27 df=2 p=0.20 I² =38.8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect</strong></td>
<td>z=1.20 p=0.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 study quality =&gt; 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fargas-Babjak 1989</td>
<td>18</td>
<td>10.72 (64.11)</td>
<td>19</td>
<td>56.05 (37.51)</td>
<td>-45.33 [-79.41, -11.25 ]</td>
</tr>
<tr>
<td>Lewis D 1984</td>
<td>29</td>
<td>4.80 (2.45)</td>
<td>29</td>
<td>5.50 (2.45)</td>
<td>-0.70 [-1.96, 0.56 ]</td>
</tr>
<tr>
<td>Yurtkuran 1999</td>
<td>25</td>
<td>0.20 (0.89)</td>
<td>25</td>
<td>1.00 (1.20)</td>
<td>-0.80 [-1.39, -0.21 ]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>72</td>
<td>73</td>
<td></td>
<td></td>
<td>-0.79 [-1.32, -0.26 ]</td>
</tr>
<tr>
<td><strong>Test for heterogeneity</strong></td>
<td>chi-square=6.58 df=2 p=0.04 I² =69.6%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect</strong></td>
<td>z=2.93 p=0.003</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

-10.0 -5.0 0 5.0 10.0
Favours treatment  Favours control

---

*Transcutaneous electrical nerve stimulation for knee osteoarthritis (Review)*

Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
### Analysis 11.02. Comparison 11 Subgroup analysis, Outcome 02 Pain relief (VAS)

Review: Transcutaneous electrical nerve stimulation for knee osteoarthritis

Comparison: 11 Subgroup analysis

Outcome: 02 Pain relief (VAS)

<table>
<thead>
<tr>
<th>Study Description</th>
<th>N</th>
<th>Mean (SD)</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight (%)</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>01 High Rate TENS vs. placebo</strong></td>
<td>Grimmer 1992</td>
<td>20</td>
<td>2.80 (3.20)</td>
<td>20</td>
<td>4.90 (3.30)</td>
</tr>
<tr>
<td></td>
<td>Lewis B 1994</td>
<td>31</td>
<td>43.20 (23.10)</td>
<td>28</td>
<td>48.10 (28.60)</td>
</tr>
<tr>
<td></td>
<td>Lewis D 1984</td>
<td>29</td>
<td>4.80 (2.45)</td>
<td>29</td>
<td>5.50 (2.45)</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>80</td>
<td>77</td>
<td>100.0</td>
<td>-1.12 [-2.18, -0.05 ]</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity chi-square=1.64 df=2 p=0.44 I² =0.0%</td>
<td>Test for overall effect z=2.06 p=0.04</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>02 Burst Mode TENS vs. placebo</strong></td>
<td>Fargas-Baljak 1989</td>
<td>18</td>
<td>10.72 (64.11)</td>
<td>19</td>
<td>56.05 (37.51)</td>
</tr>
<tr>
<td></td>
<td>Grimmer 1992</td>
<td>20</td>
<td>2.80 (3.20)</td>
<td>20</td>
<td>4.40 (1.80)</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>38</td>
<td>39</td>
<td>100.0</td>
<td>-1.70 [-3.30, -0.09 ]</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity chi-square=6.31 df=1 p=0.01 I² =84.2%</td>
<td>Test for overall effect z=2.07 p=0.04</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>03 AL-TENs vs. placebo</strong></td>
<td>Yurtkuran 1999</td>
<td>25</td>
<td>0.20 (0.89)</td>
<td>25</td>
<td>1.00 (1.20)</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>25</td>
<td>25</td>
<td>100.0</td>
<td>-0.80 [-1.39, -0.21 ]</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td>Test for overall effect z=2.68 p=0.007</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Analysis 11.03. Comparison 11 Subgroup analysis, Outcome 03 Pain relief VAS

Review: Transcutaneous electrical nerve stimulation for knee osteoarthritis

Comparison: 11 Subgroup analysis

Outcome: 03 Pain relief VAS

<table>
<thead>
<tr>
<th>Study</th>
<th>placebo</th>
<th>TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight (%)</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>95% CI</td>
<td>95% CI</td>
<td></td>
</tr>
<tr>
<td>01 Single application</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grimmer 1992</td>
<td>20 2.80 (3.20)</td>
<td>20 4.90 (3.30)</td>
<td>-2.10 [-4.11, -0.09]</td>
<td>100.0</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>20</td>
<td>20</td>
<td>-2.10 [-4.11, -0.09]</td>
<td>100.0</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect z=2.04 p=0.04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02 Repeated applications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fargas-Babjak 1989</td>
<td>18 10.72 (24.11)</td>
<td>19 56.05 (37.51)</td>
<td>-45.33 [-79.41, -11.25]</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>Lewis B 1994</td>
<td>31 43.20 (23.10)</td>
<td>28 48.10 (28.60)</td>
<td>-4.90 [-18.25, 8.45]</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td>Lewis D 1984</td>
<td>29 4.80 (2.45)</td>
<td>29 5.50 (2.45)</td>
<td>-0.70 [-1.96, 0.56]</td>
<td>15.8</td>
<td></td>
</tr>
<tr>
<td>Taylor 1981</td>
<td>10 0.90 (1.90)</td>
<td>10 0.80 (1.60)</td>
<td>0.10 [-1.44, 1.64]</td>
<td>10.6</td>
<td></td>
</tr>
<tr>
<td>Yurtkuran 1999</td>
<td>25 0.20 (0.89)</td>
<td>25 1.00 (1.20)</td>
<td>-0.80 [-1.39, -0.21]</td>
<td>73.4</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>113</td>
<td>111</td>
<td>-0.70 [-1.21, -0.20]</td>
<td>100.0</td>
<td></td>
</tr>
<tr>
<td>Test for heterogeneity chi-square=8.12 df=4 p=0.09 I² =50.7%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect z=2.75 p=0.006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 11.04. Comparison 11 Subgroup analysis, Outcome 04 Pain relief (VAS)

**Review:** Transcutaneous electrical nerve stimulation for knee osteoarthritis

**Comparison:** 11 Subgroup analysis

**Outcome:** 04 Pain relief (VAS)

<table>
<thead>
<tr>
<th>Study</th>
<th>placebo</th>
<th>TENS</th>
<th>Weighted Mean Difference (Fixed)</th>
<th>Weight (%)</th>
<th>Weighted Mean Difference (Fixed)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>95% CI</td>
</tr>
<tr>
<td>01 Studies with TENS application less than 4 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grimmer 1992</td>
<td>20</td>
<td>2.80 (3.20)</td>
<td>20</td>
<td>4.90 (3.30)</td>
<td>18.9</td>
</tr>
<tr>
<td>Lewis B 1994</td>
<td>31</td>
<td>43.20 (23.10)</td>
<td>28</td>
<td>48.10 (28.60)</td>
<td>0.4</td>
</tr>
<tr>
<td>Lewis D 1984</td>
<td>29</td>
<td>4.80 (2.45)</td>
<td>29</td>
<td>5.50 (2.45)</td>
<td>48.3</td>
</tr>
<tr>
<td>Taylor 1981</td>
<td>10</td>
<td>0.90 (1.90)</td>
<td>10</td>
<td>0.80 (1.60)</td>
<td>32.4</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>90</td>
<td>87</td>
<td>100.0</td>
<td>-0.72 [-1.60, 0.15]</td>
<td></td>
</tr>
</tbody>
</table>

Test for heterogeneity: chi-square = 3.27 df = 3 p = 0.35 I² = 8.2%

Test for overall effect z = 1.62 p = 0.1

| 02 Studies with TENS application at least 4 weeks | | | | | |
| Fargas-Babjak 1989     | 18      | 10.72 (64.11) | 19      | 56.05 (37.51) | * | 100.0 | -45.33 [-79.41, -11.25] |
| **Subtotal (95% CI)** | 18                | 19                        | 100.0 | -45.33 [-79.41, -11.25] |

Test for heterogeneity: not applicable

Test for overall effect z = 2.61 p = 0.009